JP2008517871A5 - - Google Patents

Download PDF

Info

Publication number
JP2008517871A5
JP2008517871A5 JP2007515393A JP2007515393A JP2008517871A5 JP 2008517871 A5 JP2008517871 A5 JP 2008517871A5 JP 2007515393 A JP2007515393 A JP 2007515393A JP 2007515393 A JP2007515393 A JP 2007515393A JP 2008517871 A5 JP2008517871 A5 JP 2008517871A5
Authority
JP
Japan
Prior art keywords
composition
balsalazide
administered
cancer
radiation therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007515393A
Other languages
English (en)
Japanese (ja)
Other versions
JP5009152B2 (ja
JP2008517871A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/018757 external-priority patent/WO2005117851A1/en
Publication of JP2008517871A publication Critical patent/JP2008517871A/ja
Publication of JP2008517871A5 publication Critical patent/JP2008517871A5/ja
Application granted granted Critical
Publication of JP5009152B2 publication Critical patent/JP5009152B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007515393A 2004-05-28 2005-05-27 放射線誘発性腸炎の予防、処置、および回復 Expired - Fee Related JP5009152B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60895104P 2004-05-28 2004-05-28
US60/608,951 2004-10-26
PCT/US2005/018757 WO2005117851A1 (en) 2004-05-28 2005-05-27 Prevention, treatment, and amelioration of radiation induced enteritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011233631A Division JP2012021031A (ja) 2004-10-26 2011-10-25 放射線誘発性腸炎の予防、処置、および回復

Publications (3)

Publication Number Publication Date
JP2008517871A JP2008517871A (ja) 2008-05-29
JP2008517871A5 true JP2008517871A5 (https=) 2008-07-10
JP5009152B2 JP5009152B2 (ja) 2012-08-22

Family

ID=40096437

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007515393A Expired - Fee Related JP5009152B2 (ja) 2004-05-28 2005-05-27 放射線誘発性腸炎の予防、処置、および回復

Country Status (4)

Country Link
US (3) US20080306029A1 (https=)
JP (1) JP5009152B2 (https=)
KR (1) KR20130028807A (https=)
DE (1) DE602005022175D1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012021031A (ja) * 2004-10-26 2012-02-02 Salix Pharmaceuticals Inc 放射線誘発性腸炎の予防、処置、および回復
RU2618452C1 (ru) * 2015-12-28 2017-05-03 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) Способ прогнозирования энтерита
CA3259788A1 (en) * 2022-06-22 2023-12-28 Bioventures, Llc METHOD FOR ATTENUATING INJURY BY RADIATION USING GERANYL TRANSFERASE INHIBITORS
CN115252685A (zh) * 2022-06-24 2022-11-01 内蒙古民族大学附属医院 一种蒙药巴特日-7在预防和治疗放射性肠道损伤中的应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE791889A (fr) * 1971-11-26 1973-05-24 Pharmacia Ab Nouveaux derives de la pyridine
US4298595A (en) * 1978-12-20 1981-11-03 Dynapol Pharmaceutical preparations containing a polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract
US4960765A (en) * 1980-03-20 1990-10-02 Farmaceutisk Laboratorium Ferring A/S Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration
JPS57500432A (https=) * 1980-03-20 1982-03-11
EP0039306B1 (de) * 1980-03-28 1984-01-11 Ciba-Geigy Ag Neue Azofarbstoffe, Verfahren zu deren Herstellung und deren Verwendung
US4412922A (en) * 1980-07-02 1983-11-01 Abcor, Inc. Positive-charged ultrafiltration membrane for the separation of cathodic/electrodeposition-paint compositions
US4412992A (en) * 1980-07-21 1983-11-01 Biorex Laboratories Limited 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith
ZA825384B (en) * 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
US4562024A (en) * 1982-07-06 1985-12-31 Sterling Drug Inc. Process for preparing granulate containing poorly compressible medicinally active matter
SE8405924L (sv) * 1984-11-23 1986-05-24 Pharmacia Ab Nya azoforeningar
US4781925A (en) * 1986-03-06 1988-11-01 American Home Products Corporation Calcium supplement compressed tablets
US5374430A (en) * 1986-09-18 1994-12-20 London School Of Pharmacy Pharmaceutical formulation
DE3887353T2 (de) * 1987-10-12 1994-05-05 Capability Services Pty Ltd Behandlungsverfahren für magen-darm-krankheiten.
US5064637A (en) * 1989-05-30 1991-11-12 Board Of Regents, The University Of Texas System Substituted sulfonamide derivatives which inhibit allergic reactions
US5095073A (en) * 1990-03-02 1992-03-10 Exxon Research And Engineering Company Water soluble rigid rod sulfonated aromatic polyamide
US5519014A (en) * 1990-10-22 1996-05-21 Borody; Thomas J. Treatment of non-inflammatory and non-infectious bowel disorders
ATE160696T1 (de) * 1992-03-11 1997-12-15 Asta Medica Ag Tabletten, granulate und pellets mit hohem gehalt an wirkstoffen für hochkonzentrierte, feste darreichungsformen
US5498608A (en) * 1994-01-07 1996-03-12 Salix Pharmaceuticals Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
US6562629B1 (en) * 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6231888B1 (en) * 1996-01-18 2001-05-15 Perio Products Ltd. Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps
SE9700934D0 (sv) * 1997-03-14 1997-03-14 Astra Ab New formulation
US6551632B2 (en) * 1997-04-01 2003-04-22 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
EP0971735B1 (en) * 1997-04-01 2008-03-19 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
AUPO665397A0 (en) * 1997-05-07 1997-05-29 Borody, Thomas Julius Novel therapy for constipation
US6144381A (en) * 1997-05-14 2000-11-07 International Business Machines Corporation Systems, methods and computer program products for compass navigation of avatars in three dimensional worlds
DE19732903A1 (de) * 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
US5927500A (en) * 1998-06-09 1999-07-27 Milliken & Company Pharmaceutical containment package
AUPP437698A0 (en) * 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
NZ509378A (en) * 1998-07-20 2003-04-29 Smithkline Beecham Corp Amorphous ammonium salts of eprosartan and pharmaceuticals thereof, useful for blocking angiotensin II receptors and useful for treating hypertension, congestive heart disease and renal failure
US6326364B1 (en) * 1999-02-08 2001-12-04 Cedars-Sinai Medical Center Use of 5-aminosalicylates as antimicrobial agents
US20030138399A1 (en) * 1999-05-14 2003-07-24 Anton Peter A. Anti-inflammatory therapy for inflammatory mediated infection
DK1313697T3 (da) * 2000-08-29 2006-04-10 Nobex Corp Immunregulatoriske forbindelser, derivater deraf samt anvendelse deraf
ATE460394T1 (de) * 2000-08-29 2010-03-15 Biocon Ltd 5-asa-derivate mit entzündungshemmender und antibiotischer wirkung und verfahren zur behandlung von krankheiten mit diesen derivaten
US6562871B1 (en) * 2000-11-06 2003-05-13 Boehringer Ingelheim Pharmaceuticals, Inc. Dry granulation of pharmaceutical formulation comprising mexiletine
CA2359812C (en) * 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
AU2002318935A1 (en) * 2001-07-31 2003-02-17 The General Hospital Corporation Methods and compositions for treating and preventing distal bowel lesions
US6407128B1 (en) * 2001-12-03 2002-06-18 Elan Pharmaceuticals, Inc. Method for increasing the bioavailability of metaxalone
US20030190352A1 (en) * 2002-03-28 2003-10-09 Synthon Bv Compositions of venlafaxine base
US20060177444A1 (en) * 2003-03-20 2006-08-10 Tatsuo Horizoe Concomitant drug as therapeutic agent for inflammatory bowel disease
US7737133B2 (en) * 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
US7825106B2 (en) * 2003-09-03 2010-11-02 Agi Therapeutics Ltd. Modified release formulations and methods of treating inflammatory bowel disease
US7452872B2 (en) * 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
EP2529729A1 (en) * 2005-08-24 2012-12-05 Salix Pharmaceuticals, Inc. Balsalazide formulations and manufacture thereof
US20100048519A1 (en) * 2006-09-13 2010-02-25 Chyon-Hwa Yeh Methods of treatment for ulcerative colitis using aminosalicylate

Similar Documents

Publication Publication Date Title
JP2009545602A5 (ja) 放射線直腸ｓ状結腸炎を処置するための組成物および方法
MX342894B (es) Dosis de inmunoconjugados de anticuerpos y sn-38 para eficacia mejorada y toxicidad reducida.
TR201807411T4 (tr) DNA-PK inhibitörleri.
MX2009006779A (es) Antagonistas especificos para terapia con adyuvantes y neo-adyuvantes y el tratamiento de tumores en etapa temprana.
JP2017039771A5 (https=)
NZ621449A (en) Treatment with anti-vegf antibodies
NO20053782L (no) Behandling av kreft med 2-deoksyglukose
JP2023168298A5 (https=)
EA201391286A1 (ru) Лечение солидных опухолей
JP2019529476A5 (https=)
JP2021105005A5 (https=)
Le et al. Complete response of a stage IV uterine papillary serous carcinoma to neoadjuvant chemotherapy with Taxol and carboplatin
Hasenburg et al. Evaluation of patients after extraperitoneal lymph node dissection and subsequent radiotherapy for cervical cancer
JP2008517871A5 (https=)
WO2005087206A3 (en) Cancer therapy comprising a nuclear receptor ligand and a hdac inhibitor
WO2019017497A1 (en) USE OF CYCLIN-DEPENDENT KINASE ERIBULINE AND INHIBITORS IN THE TREATMENT OF CANCER
ATE499378T1 (de) Anthracyclinderivate
CA2556373A1 (en) Prevention, treatment, and amelioration of radiation induced enteritis
HARIMA et al. Preliminary study of the combination of radiation therapy, chemotherapy, and hyperthermia in Stage IIIB cervical carcinoma
Xiao-yan et al. Research Progress on Chemotherapy of Endometrial Carcinoma
Suprasert et al. Efficacy of Cisplatin in Early Stage Cervical Cancer With Long Waiting Period for Surgery
Padovani et al. Chemotherapy in Rectal Cancer
Hirowatari et al. Full-dose capecitabine with local radiotherapy: one of the treatment options for inoperable T4 breast cancer
Xue et al. Advances in the Treatment of Vulvar Squamous Cell
Sharma et al. Concurrent Chemoradiotherapy in Patients With Cervical Carcinoma: Our Institutional Experience